<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359966</url>
  </required_header>
  <id_info>
    <org_study_id>SZGH Krka</org_study_id>
    <nct_id>NCT04359966</nct_id>
  </id_info>
  <brief_title>Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia</brief_title>
  <official_title>Prospective Randomised Trial of First and Second Line Treatments of Helicobacter Pylori Infection in Slovenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Slovenian Society for Gastroenterology and Hepatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KRKA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Slovenian Society for Gastroenterology and Hepatology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is prospective randomised multicentric. The primary objective of the study is to
      compare the efficacy of two first-line therapy regimens and two second-line therapy regimens
      (ie, after failure of first-line treatment) in patients with H. pylori infection. The
      secondary objective of the study is to determine the primary resistance of H. pylori to
      antibiotics in Slovenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The infection with Helicobacter pylori is extremely widespread, as 60% of the world's
      population is infected. In Slovenia, the average prevalence is 25.1 %, the prevalence in the
      20-year age group is 20 % and 76 % in patients in age group 50 - 75 years. All infected
      patients have active chronic gastritis, which is asymptomatic in most cases. Ulcers in the
      stomach or duodenum occurs in 15 % of patients. Due to chronic infection, MALT lymphoma or
      gastric cancer develop in 1 - 3 % of patients. According to the recommendations of the
      Slovenian Association for Gastroenterology and Hepatology, as well as European and other
      recommendations, everyone who is infected with Helicobacter pylori should be treated. H.
      pylori is a first-class carcinogen and is responsible for 50 % of all chronic cancer-causing
      infections in the developed world. Therefore, it is necessary to start programs of primary
      and secondary prevention of gastric cancer by searching and treating infected patients.

      Patients infected with H. pylori who have not yet been treated will be randomly assigned to
      two first-line treatment groups:

      Group 1: Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID,14 days
      Group 2: Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg, all QID
      Esomeprazole 40 mg BID, 14 days

      Patients unsuccessfully treated with first-line therapy will be randomly assigned to two
      second-line treatment groups:

      Group 1: Esomeprazole 40 mg BID, Levofloxacin 500 mg OID, Amoxicillin 1000 mg BID, 14 days
      Group 2: Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg, all QID,
      Esomeprazole 40 mg BID, 14 days

      Inclusion criteria :

      Patients 18 to 80 years of age. Patients have not received proton pump inhibitors for the
      past 14 days. Patients did not receive antibiotics last month. Helicobacter pylori infection
      has been demonstrated by rapid urease test

      Exclusion criteria :

      Prior treatment for Helicobacter pylori infection (in patients who will receive Schedule 1
      eradication therapy).

      Defects in blood clotting. taking anticoagulant medicines that make it impossible to take
      biopsies.

      Drug allergy used in the study. Pregnancy, breastfeeding. Psychiatric illness that would
      prevent research participation. Active treatment for malignancy.

      Statistical analysis:

      To describe the variables, we will use the average value and standard deviation for the
      symmetrically distributed variables or median and 25th and 75th percentiles for
      asymmetrically distributed variables. Investigators will use the t-test for dependent
      variables or, in the case of asymmetrically distributed variables, the Wilcoxon test. To
      determine the differences between the two groups (Group 1 and Group 2) of the subjects,
      t-test for independent samples Will be used, or in the case of an asymmetrically distributed
      variables Mann-Whitney test.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised procpective multicenter trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of first line therapy for Helicobacter pylori infection</measure>
    <time_frame>2 years</time_frame>
    <description>Eradication rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate of second line therapy for Helicobacter pylori infection</measure>
    <time_frame>3 years</time_frame>
    <description>Eradication rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Helicobacter pylori resistance rate to antibiotics</measure>
    <time_frame>3 years</time_frame>
    <description>Culture and susceptibility testing</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Eradication Treatments</condition>
  <arm_group>
    <arm_group_label>First line therapy for H pylori infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First line therapy for H pylori infection second arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bismuth quadruple first line therapy
Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second line therapy for H pylori infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth quadruple second line therapy for those treated with Tripple first line therapy
Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second line therapy for H pylori infection second arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tripple second line therapy
Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,</intervention_name>
    <description>First line therapy</description>
    <arm_group_label>First line therapy for H pylori infection</arm_group_label>
    <other_name>Emozul, Fromilid,Efloran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg</intervention_name>
    <description>First line therapy second arm</description>
    <arm_group_label>First line therapy for H pylori infection second arm</arm_group_label>
    <other_name>Emozul, Bismut oksid Krka, Hiconcil, Efloran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg</intervention_name>
    <description>Second line therapy for Helicobacter pylori infection</description>
    <arm_group_label>Second line therapy for H pylori infection</arm_group_label>
    <other_name>Emozul, Bismut oksid Krka, Hiconcil, Efloran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg</intervention_name>
    <description>Second line therapy for Helicobacter pylori infection second arm</description>
    <arm_group_label>Second line therapy for H pylori infection second arm</arm_group_label>
    <other_name>Emozul, Hiconcil,Tavanic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients 18 to 80 years of age.

          -  Patients have not received proton pump inhibitors for the past 14 days.

          -  Patients did not receive antibiotics in the last month.

          -  Helicobacter pylori infection has been demonstrated by rapid urease test.

        Exclusion Criteria:

          -  Prior treatment for Helicobacter pylori infection (in patients who will receive
             Schedule 1 eradication therapy).•

          -  Defects in blood clotting. taking anticoagulant medicines that make it impossible to
             take biopsies.

          -  Allergy to drugs used in the study.

          -  Pregnancy, breastfeeding shold be excluded.

          -  Psychiatric illness that would prevent research participation.

          -  Active treatment for malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BOJAN TEPES</last_name>
    <role>Principal Investigator</role>
    <affiliation>AM DC Rogaška</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BOJAN TEPES</last_name>
    <phone>0038641325916</phone>
    <phone_ext>0038641325916</phone_ext>
    <email>bojan.tepes@siol.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>DC BLED</name>
      <address>
        <city>Bled</city>
        <zip>4260</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Milan Stefanovič</last_name>
      <email>milan.stefanovic@dc-bled.si</email>
    </contact>
    <investigator>
      <last_name>Milan Stefanovič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCC</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Borut Stabuc, MD PhD</last_name>
      <email>borut.stabuc@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Borut Stabuc, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Am Dc Rogaska</name>
      <address>
        <city>Rogaška Slatina</city>
        <zip>3250</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Prof B TEPES</last_name>
      <phone>0038641325916</phone>
      <phone_ext>0038641325916</phone_ext>
      <email>bojan.tepes@siol.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>First line treatment</keyword>
  <keyword>Second line treatment</keyword>
  <keyword>susceptibility to antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

